Differential pricing of drugs: A role for cost-effectiveness analysis?

Ruth Lopert, Danielle L. Lang, Suzanne R. Hill, David A. Henry

Research output: Contribution to journalShort surveyResearchpeer-review

21 Citations (Scopus)

Abstract

Internationally, the high costs of pharmaceutical products limit access to treatment. The principle of differential pricing is that drug prices should vary according to some measure of affordability. How differential prices should be determined is, however, unclear. Here we describe a method whereby differential prices for essential drugs could be derived in countries of variable national wealth, and, using angiotensin-converting enzyme inhibitors provide an example of how the process might work. Indicative prices for drugs can be derived by cost-effectiveness analysis that incorporates a measure of national wealth. Such prices could be used internationally as a basis of differential price negotiations.

Original languageEnglish
Pages (from-to)2105-2107
Number of pages3
JournalLancet
Volume359
Issue number9323
DOIs
Publication statusPublished - 15 Jun 2002
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Costs and Cost Analysis
Pharmaceutical Preparations
Essential Drugs
Negotiating
Angiotensin-Converting Enzyme Inhibitors

Cite this

Lopert, Ruth ; Lang, Danielle L. ; Hill, Suzanne R. ; Henry, David A. / Differential pricing of drugs : A role for cost-effectiveness analysis?. In: Lancet. 2002 ; Vol. 359, No. 9323. pp. 2105-2107.
@article{694d042b9aa6478dbbe09b0a3edd0e24,
title = "Differential pricing of drugs: A role for cost-effectiveness analysis?",
abstract = "Internationally, the high costs of pharmaceutical products limit access to treatment. The principle of differential pricing is that drug prices should vary according to some measure of affordability. How differential prices should be determined is, however, unclear. Here we describe a method whereby differential prices for essential drugs could be derived in countries of variable national wealth, and, using angiotensin-converting enzyme inhibitors provide an example of how the process might work. Indicative prices for drugs can be derived by cost-effectiveness analysis that incorporates a measure of national wealth. Such prices could be used internationally as a basis of differential price negotiations.",
author = "Ruth Lopert and Lang, {Danielle L.} and Hill, {Suzanne R.} and Henry, {David A.}",
year = "2002",
month = "6",
day = "15",
doi = "10.1016/S0140-6736(02)08911-0",
language = "English",
volume = "359",
pages = "2105--2107",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "9323",

}

Differential pricing of drugs : A role for cost-effectiveness analysis? / Lopert, Ruth; Lang, Danielle L.; Hill, Suzanne R.; Henry, David A.

In: Lancet, Vol. 359, No. 9323, 15.06.2002, p. 2105-2107.

Research output: Contribution to journalShort surveyResearchpeer-review

TY - JOUR

T1 - Differential pricing of drugs

T2 - A role for cost-effectiveness analysis?

AU - Lopert, Ruth

AU - Lang, Danielle L.

AU - Hill, Suzanne R.

AU - Henry, David A.

PY - 2002/6/15

Y1 - 2002/6/15

N2 - Internationally, the high costs of pharmaceutical products limit access to treatment. The principle of differential pricing is that drug prices should vary according to some measure of affordability. How differential prices should be determined is, however, unclear. Here we describe a method whereby differential prices for essential drugs could be derived in countries of variable national wealth, and, using angiotensin-converting enzyme inhibitors provide an example of how the process might work. Indicative prices for drugs can be derived by cost-effectiveness analysis that incorporates a measure of national wealth. Such prices could be used internationally as a basis of differential price negotiations.

AB - Internationally, the high costs of pharmaceutical products limit access to treatment. The principle of differential pricing is that drug prices should vary according to some measure of affordability. How differential prices should be determined is, however, unclear. Here we describe a method whereby differential prices for essential drugs could be derived in countries of variable national wealth, and, using angiotensin-converting enzyme inhibitors provide an example of how the process might work. Indicative prices for drugs can be derived by cost-effectiveness analysis that incorporates a measure of national wealth. Such prices could be used internationally as a basis of differential price negotiations.

UR - http://www.scopus.com/inward/record.url?scp=0037097042&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)08911-0

DO - 10.1016/S0140-6736(02)08911-0

M3 - Short survey

VL - 359

SP - 2105

EP - 2107

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9323

ER -